
    
      Primary objective:

      Progression-free survival

      Secondary objective:

      Overall survival, best objective response, disease control rate, time to progression,
      duration of treatment and adverse events

      Number of Subjects: 153 patients with metastatic colorectal cancer treated with regorafenib
      and FOLFIRI as a third- or fourth-line setting.

      Plan of the Study:

        1. This is a prospective, multicenter, randomized in a 2:1 ratio, controlled study.

        2. Study Schedule Study date: the time getting approval letter issued by both regulatory
           authority and institutional review board (IRB). Duration of the study: 4 years.

        3. Duration of Treatment: Treatment was administered until disease progressed.
    
  